Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Fang Zhao, Jie Wang, Liu Yao, Yu-ting Qin, Niluopaer Tuerxun, Huan Wang, Ming Jiang & Jian-ping Hao. (2021) Synergistic inhibitory effect of Smo inhibitor jervine and its combination with decitabine can target Hedgehog signaling pathway to inhibit myelodysplastic syndrome cell line. Hematology 26:1, pages 518-528.
Read now
Read now
Yuan-yuan Ma, Min Zhao, Yi Liu, De-feng Zhao, Li-xin Wang, Xiao-ping Chen & Li Li. (2019) Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis. Hematology 24:1, pages 507-515.
Read now
Read now
Xinwei Shi, Ping Chen, Hao Liu, Fuyuan Qiao, Haiyi Liu, Xun Gong, Yuqi Li, Hui Du, Wanlu Liu, Guiju Tang, Jing Cao & Yuanyuan Wu. (2015) Decitabine Improves the Clinical Manifestations of Rats With l-NAME-Induced Pre-eclampsia: A Potential Approach to Studying Pre-eclampsia. Hypertension in Pregnancy 34:4, pages 464-473.
Read now
Read now
Jeffrey Bryan, Hagop Kantarjian, Guillermo Garcia-Manero & Elias Jabbour. (2011) Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opinion on Drug Metabolism & Toxicology 7:5, pages 661-672.
Read now
Read now
Alvin Gomez & Magnus Ingelman-Sundberg. (2009) Pharmacoepigenetic aspects of gene polymorphism on drug therapies: effects of DNA methylation on drug response. Expert Review of Clinical Pharmacology 2:1, pages 55-65.
Read now
Read now
Tapan M Kadia & Guillermo Garcia-Manero. (2008) Role of epigenetic therapy in myelodysplastic syndrome. Expert Review of Hematology 1:2, pages 161-174.
Read now
Read now
Articles from other publishers (18)
Haodong Ding, Yuwei Li, Maoxin Fang, Jiaojiao Chen, Lipin Liu, Zhigang Lu, Jia Hou & Min Luo. (2023) Epigenetic activation of the TUSC3 gene as a potential therapy for XMEN disease. Journal of Allergy and Clinical Immunology 151:6, pages 1622-1633.e10.
Crossref
Crossref
Sung-Eun Lee, Feng Wang, Maison Grefe, Abel Trujillo-Ocampo, Wilfredo Ruiz-Vasquez, Koichi Takahashi, Hussein A. Abbas, Pamella Borges, Dinler Amaral Antunes, Gheath Al-Atrash, Naval Daver, Jeffrey J. Molldrem, Andrew Futreal, Guillermo Garcia-Manero & Jin S. Im. (2023) Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes. Clinical Cancer Research 29:10, pages 1938-1951.
Crossref
Crossref
Côme Thieulent, Erika S. Hue, Gabrielle Sutton, Christine Fortier, Patrick Dallemagne, Stephan Zientara, Hélène Munier-Lehmann, Aymeric Hans, Romain Paillot, Pierre-Olivier Vidalain & Stéphane Pronost. (2020) Identification of antiviral compounds against equid herpesvirus-1 using real-time cell assay screening: Efficacy of decitabine and valganciclovir alone or in combination. Antiviral Research 183, pages 104931.
Crossref
Crossref
Hemant Gujar, Daniel Weisenberger & Gangning Liang. (2019) The Roles of Human DNA Methyltransferases and Their Isoforms in Shaping the Epigenome. Genes 10:2, pages 172.
Crossref
Crossref
Chao Niu, Min Li, Shan Zhu, Yongchong Chen, Lei Zhou, Dongsheng Xu, Wei Li, Jiuwei Cui, Yongjun Liu & Jingtao Chen. (2018) Decitabine Inhibits Gamma Delta T Cell Cytotoxicity by Promoting KIR2DL2/3 Expression. Frontiers in Immunology 9.
Crossref
Crossref
Tatjana Maria Swerev, Thomas Wirth & Alexey Ushmorov. (2017) Activation of oncogenic pathways in classical Hodgkin lymphoma by decitabine: A rationale for combination with small molecular weight inhibitors. International Journal of Oncology 50:2, pages 555-566.
Crossref
Crossref
Metin Karahoca & Richard L Momparler. (2013) Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clinical Epigenetics 5:1.
Crossref
Crossref
Hanfeng Guan, Linka Xie, Kay Klapproth, Clarissa D Weitzer, Thomas Wirth & Alexey Ushmorov. (2013)
Decitabine represses translocated
MYC
oncogene in Burkitt lymphoma
. The Journal of Pathology 229:5, pages 775-783.
Crossref
Crossref
Mengyong Yan, Nourredine Himoudi, B. Piku Basu, Rebecca Wallace, Edmund Poon, Stuart Adams, Fyeza Hasan, Shao-An Xue, Natalie Wilson, Angus Dalgleish, Owen Williams & John Anderson. (2011) Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2′-Deoxycytidine. Cancer Immunology, Immunotherapy 60:9, pages 1243-1255.
Crossref
Crossref
Jeffrey Bryan, Elias Jabbour, Hillary Prescott, Guillermo Garcia-Manero, Jean-Pierre Issa & Hagop Kantarjian. (2010) Current and Future Management Options for Myelodysplastic Syndromes. Drugs 70:11, pages 1381-1394.
Crossref
Crossref
Chie Nishioka, Takayuki Ikezoe, Jing Yang, Naoki Komatsu, H. Phillip Koeffler & Akihito Yokoyama. (2009) Blockade of MEK signaling potentiates 5-Aza-2′-deoxycytidine-induced apoptosis and upregulation of p21waf1 in acute myelogenous leukemia cells. International Journal of Cancer 125:5, pages 1168-1176.
Crossref
Crossref
A. A. Evdokimov, V. V. Zinoviev, V. V. Kuznetsov, N. A. Netesova & E. G. Malygin. (2009) Design of oligonucleotide inhibitors for human DNA methyltransferase 1. Molecular Biology 43:3, pages 418-425.
Crossref
Crossref
Ina Patties, Jutta Jahns, Guido Hildebrandt, Rolf-Dieter Kortmann & Annegret Glasow. (2009) Additive Effects of 5-Aza-2’-deoxycytidine and Irradiation on Clonogenic Survival of Human Medulloblastoma Cell LinesAdditive Effekte von 5-Aza-2’-deoxycytidin und Bestrahlung auf das klonogene Überleben von humanen Medulloblastomzelllinien. Strahlentherapie und Onkologie 185:5, pages 331-338.
Crossref
Crossref
Shan Gao, Aaron Mobley, Claudia Miller, Jessica Boklan & Joya Chandra. (2008) Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. Leukemia Research 32:5, pages 771-780.
Crossref
Crossref
Vladimir Beljanski. 2008. xPharm: The Comprehensive Pharmacology Reference. xPharm: The Comprehensive Pharmacology Reference
1
5
.
Bruce A. Feinberg, James Gilmore, Wendy Hawke Lenz, Carlos M. Franco, Tom Gondesen & Mansoor N. Saleh. (2007) Changing Treatment Paradigms for Myelodysplastic Syndromes in a Community Oncology Practice: Georgia Cancer Specialists' Experience. Clinical Leukemia 1:6, pages 345-352.
Crossref
Crossref
. (2007) Current Awareness in Hematological Oncology. Hematological Oncology 25:3, pages 148-155.
Crossref
Crossref
Shridhar Hegde & Michelle Schmidt. 2007. Annual Reports in Medicinal Chemistry Volume 42. Annual Reports in Medicinal Chemistry Volume 42
505
554
.